Molecular imaging with radiolabeled bevacizumab in metastatic colon carcinoma. A feasibility study in patients who do show response on bevacizumab therapy - Molecular imaging with radiolabeled bevacizumab in colon carcinoma

niversitair Medisch Centrum Groningen0 个研究点目标入组 6 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•1. Metastatic colon cancer.
•2. Decrease in CEA levels [-25%] after the 1st or 2nd cycle of first line chemotherapy, including bevacizumab, or decrease in size of measurable valuable lesion.
•3. At least 18 years of age.
•4. A life expectancy of at least 3 months.
•5. Adequate hematologic, hepatic, and renal function.
•6. Signed written informed consent.
•7. Able to comply with the protocol.

•1. Prior chemotherapy or biological therapy for metastatic disease.
•2. Radiotherapy within 14 days before the start of the study of the involved area.
•3. Major surgery within 28 days before the initiation of the study.
•4. Clinically significant cardiovascular disease.
•5. Pregnant or lactating women. Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause.
•6. CNS metastases (CT-scan not mandatory).
•7. Treatment with any investigational drug within 30 days before the start of the study.
•8. Prior allergic reaction to immunoglobulins or immunoglobulin allergy.

发起方